(Q43515272)

24 November 2017

A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study (English)

1 reference

24 November 2017

visceral leishmaniasis

1 reference

1 reference

Thakur CP

1

1 reference

24 November 2017

1 January 2001

1 reference

International Journal of Antimicrobial Agents

24 November 2017

1 reference

24 November 2017

17

1 reference

24 November 2017

1

1 reference

24 November 2017

67-70

1 reference

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Comparison of Regimes of Treatment of Antimony-Resistant Kala-Azar Patients: A Randomized Study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Amphotericin B for second-line treatment of Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

AMPHOTERICIN B TOXICITY; GENERAL SIDE EFFECTS.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

A pharmacologic guide to the clinical use of amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Sodium antimony gluconate, amphotericin, and myocardial damage

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

Comparative Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex and Amphotericin B Desoxycholate in Healthy Male Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900312-5

7 January 2021

10.1016/S0924-8579(00)00312-5

Identifiers

DOI

1 reference

24 November 2017

1 reference

PubMed ID

11137652